Pre-screening of the gut microbiome may lead to a more personalized approach to treating intestinal parasitic worm infections, leading to better treatment outcomes and a decreased risk for drug resistance.
Before its COVID-19 era hype, ivermectin was already a wonder drug for parasitic infections. Its renewed interest underscores the need for effective COVID-19 treatments and communication on proper research study design and analysis.